Home

Gouverner Fabrication Commerce novartis zolgensma press release Rappeler éternuement Démêler

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Novartis used faulty data for world's most expensive drug Zolgensma
Novartis used faulty data for world's most expensive drug Zolgensma

Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve | Fierce Pharma
Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve | Fierce Pharma

Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR
Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR

Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor

FDA Accepts AveXis' BLA for SMA Drug Zolgensma Under Priority Review - Muscular Dystrophy Association
FDA Accepts AveXis' BLA for SMA Drug Zolgensma Under Priority Review - Muscular Dystrophy Association

$2.1m Novartis gene therapy to become world's most expensive drug | Drugs | The Guardian
$2.1m Novartis gene therapy to become world's most expensive drug | Drugs | The Guardian

Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing - Cure SMA
Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing - Cure SMA

AMM européenne pour Scemblix® (asciminib) de Novartis
AMM européenne pour Scemblix® (asciminib) de Novartis

Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters
Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters

Novartis faces serious delays in registration of Zolgensma in Russia
Novartis faces serious delays in registration of Zolgensma in Russia

Novartis says it knew of Zolgensma data problems before U.S. approval - The Japan Times
Novartis says it knew of Zolgensma data problems before U.S. approval - The Japan Times

Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO | Fierce Pharma
Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO | Fierce Pharma

Novartis releases long-term data for SMA gene therapy
Novartis releases long-term data for SMA gene therapy

Zolgensma gene therapy for sma patients: long-term data
Zolgensma gene therapy for sma patients: long-term data

Novartis' Zolgensma expansion hits FDA roadblock, giving Biogen and Roche a reprieve | Fierce Pharma
Novartis' Zolgensma expansion hits FDA roadblock, giving Biogen and Roche a reprieve | Fierce Pharma

Novartis Boosts Zolgensma Production Capacity After FDA Clearance
Novartis Boosts Zolgensma Production Capacity After FDA Clearance

Novartis to Open New Trial of Zolgensma for Older SMA Patients
Novartis to Open New Trial of Zolgensma for Older SMA Patients

Japan's health insurance to cover ¥167 million gene therapy drug - The Japan Times
Japan's health insurance to cover ¥167 million gene therapy drug - The Japan Times

EMA seeks to issue guidance on liver damage from Novartis' gene therapy | Reuters
EMA seeks to issue guidance on liver damage from Novartis' gene therapy | Reuters

Novartis Media Release guide - August 2019
Novartis Media Release guide - August 2019

Novartis Reveals Two Deaths Related to SMA Drug Zolgensma | BioSpace
Novartis Reveals Two Deaths Related to SMA Drug Zolgensma | BioSpace

Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge

R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence
R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence

Novartis's SMA gene therapy Zolgensma to be available for NHS use - Pharmaceutical Technology
Novartis's SMA gene therapy Zolgensma to be available for NHS use - Pharmaceutical Technology